Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Elucidating biomarkers of response in the RELATIVITY-047 trial

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on results of a biomarker analysis from the Phase II/III RELATIVITY-047 (NCT03470922) of relatlimab with nivolumab in patients with advanced, untreated cutaneous melanoma. Combining relatlimab with nivolumab resulted in improved progression-free survival, especially in patients with lower CD8+ T-cell infiltration. However, PD-L1-positive patients were shown to not benefit as much from the combination therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.